Povorcitinib + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Oct 10, 2024 → May 3, 2027

NCT ID

NCT06516965

About Povorcitinib + Placebo

Povorcitinib + Placebo is a phase 3 stage product being developed by Incyte for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06516965. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

1 of 6 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (5)

✅UpadacitinibAbbVieApproved

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄DupilumabSanofiPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06516952	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06516965	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06113445	Phase 3	Active	Nov 29, 2023	Feb 24, 2027	NonSegmental Vitiligo
NCT06113471	Phase 3	Active	Nov 27, 2023	Mar 16, 2027	NonSegmental Vitiligo
NCT05936567	Phase 2	Completed	Jul 31, 2023	Oct 9, 2025	Urticaria
NCT05620836	Phase 3	Completed	Feb 22, 2023	Nov 21, 2025	Hidradenitis Suppurativa (HS)
NCT05620823	Phase 3	Completed	Dec 19, 2022	Dec 23, 2025	Hidradenitis Suppurativa (HS)

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25